Ipilimumab addition to nivolumab showed no significant clinical benefit in resected advanced stage melanoma
Ipilimumab addition to nivolumab showed no significant clinical benefit in resected advanced stage...
Read MoreOct 11, 2022
Ipilimumab addition to nivolumab showed no significant clinical benefit in resected advanced stage...
Read MoreOct 11, 2022
1. Almost half of patients (47%) had either an objective response or had progression free survival...
Read MoreOct 11, 2022
1. Median progression free survival was longer in the fulvestrant and palbociclib group compared...
Read MoreSep 28, 2022
1. Selpercatinib was found to have similar effective objective response rates compared to past...
Read MoreSep 28, 2022
1. Objective response rate was 43.9%. Patients treated with selpercatinib also experienced...
Read MoreSep 28, 2022
1. Patients in the active surveillance group who had forgone surgery had no difference in survival...
Read MoreSep 28, 2022
1. 25.8% of patients receiving chemotherapy for breast cancer experienced worsening frailty status. 2. Patients with both biomarkers (IL-6 and CRP) elevated before chemotherapy had a significantly higher risk of decline in...
Read MoreSep 22, 2022
1. Adjuvant pembrolizumab significantly improved disease-free survival in comparison to placebo in...
Read MoreSep 22, 2022
1. After neoadjuvant treatment with celmiplimab, half of the patients were found to have a...
Read MoreSep 22, 2022
1. Hepatocellular carcinoma (HCC) tumours located in ultrasound (US) blind spots were associated...
Read MoreSep 22, 2022
1. Patients who had never previously received anti-angiogenesis treatments had longer...
Read MoreSep 13, 2022
1. Median disease-free survival is longer in patients receiving mFOLFIRINOX as compared to those...
Read MoreSep 13, 2022
1. There is no significant difference for perceived dyspnea in patients taking dexamethasone as...
Read MoreSep 13, 2022
1. Telaglenastat addition to cabozantinib did not show improvements in clinical benefit. 2....
Read MoreSep 6, 2022
1. In a very large retrospective cohort of hospitalized pediatric patients, the incidence of C....
Read MoreSep 6, 2022
1. Erlotinib showed an overall survival benefit and improved 5-year survival rates when compared...
Read MoreSep 6, 2022
1. Median progression-free survival was longer in the SG group than in the chemotherapy group. 2....
Read MoreAug 31, 2022
Evaluating specific types of medications an older patient with blood cancer is taking is more...
Read MoreAug 24, 2022
1. Supervised exercise interventions significantly improved muscle strength, daily physical...
Read MoreAug 16, 2022
1. A high risk of incident lung cancer exists for smokers that do not meet low-dose computed...
Read More